NDAORALTABLET
Approved
Jul 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
BRILINTA (ticagrelor) by AstraZeneca is p2y12 receptor antagonists [moa]. First approved in 2011.
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRILINTA (ticagrelor) is an oral P2Y12 platelet inhibitor approved in 2011 for acute coronary syndromes and secondary prevention of thrombotic events. It works by reversibly blocking the P2Y12 receptor on platelets, reducing platelet aggregation and clot formation. The drug is indicated for patients at high risk of cardiovascular events, particularly those with acute myocardial infarction or unstable angina.
$0.692BPart D
PeakStable
10.1 years to LOEMature peak-stage asset generating substantial Part D revenue with stable prescription volume, indicating established brand team focused on market retention and life-cycle management.
Mechanism of Action
P2Y12 Receptor Antagonists
Pharmacologic Class:
P2Y12 Platelet Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants
Started Aug 2024
28 enrolled
Healthy Participants
Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg
Started Jun 2024
36 enrolled
Healthy Subjects
Ticagrelor De-escalation Strategy in AMI Patients
Started Mar 2023
2,312 enrolled
Acute Myocardial Infarction
Disparities in the Proportion of Ticagrelor and Prasugrel-eligible Patients with Acute Coronary Syndrome in a Real-world Registry
Started Mar 2023
6,789 enrolled
Acute Myocardial Infarction
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
Started Mar 2022
58 enrolled
Coronary Artery DiseaseHealthy Participants
Worked on BRILINTA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.